Myriad, Rival Strike Deal In Cancer-Test Patent Dispute

Law360, Los Angeles (February 7, 2014, 3:43 PM EST) -- Myriad Genetics Inc. has settled its suit against Gene by Gene Ltd. over alleged infringement of its cancer-testing patents, including several that were upheld in a landmark U.S. Supreme Court decision last year, with Gene by Gene agreeing to stop offering the tests in North America, the companies said Friday.

Myriad agreed to drop claims that Houston-based Gene by Gene's genetic testing infringed nine of its patents, according to a joint statement by the companies. In return, Gene by Gene said it would stop selling and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.